Nuvation Bio (NUVB) Capital Expenditures (2020 - 2026)
Nuvation Bio (NUVB) posted quarterly Capital Expenditures of $48000.0 for Q1 2026, down 33.33% year-over-year from $72000.0 in Q1 2025, and up 100.63% quarter-over-quarter from -$7.6 million in Q4 2025.
Nuvation Bio (NUVB) Capital Expenditures (2020 - 2026) Analysis & Trends
Nuvation Bio (NUVB) has reported Capital Expenditures for 7 consecutive years, with $48000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Capital Expenditures fell 33.33% year-over-year to $48000.0; the TTM figure through Mar 2026 stood at $330000.0 (down 94.57% YoY), while the FY2025 annual figure was $354000.0, down 94.13% from the prior year.
- Capital Expenditures rose to $48000.0 in Q1 2026 per NUVB's latest filing, from -$7.6 million in the prior quarter.
- Across five years, Capital Expenditures topped out at $8.1 million in Q3 2025 and bottomed at -$7.6 million in Q4 2025.
- Historically, Capital Expenditures has averaged $491000.0 across 5 years, with a median of $37500.0 in 2024.
- Annual changes were most pronounced in 2022 — Capital Expenditures slumped 796.55% — and 2024, when it soared 47107.69%.
- Nuvation Bio's Capital Expenditures stood at $370000.0 in 2022, then tumbled by 96.49% to $13000.0 in 2023, then jumped by 47107.69% to $6.1 million in 2024, then slumped by 224.59% to -$7.6 million in 2025, then soared by 100.63% to $48000.0 in 2026.
- Business Quant data shows NUVB's Capital Expenditures at $48000.0 in Q1 2026, -$7.6 million in Q4 2025, and $8.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Nuvation Bio | 2.16 Bn | 2.16 Bn | 30.78 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 48,000.00 |
| Mar 31, 2026 | 48,000.00 |
| Dec 31, 2025 | -7.65 Mn |
| Dec 31, 2025 | -7.65 Mn |
| Sep 30, 2025 | 8.15 Mn |
| Sep 30, 2025 | 8.15 Mn |
| Jun 30, 2025 | -217,000.00 |
| Jun 30, 2025 | -217,000.00 |
| Mar 31, 2025 | 72,000.00 |
| Mar 31, 2025 | 72,000.00 |
| Dec 31, 2024 | 6.14 Mn |
| Dec 31, 2024 | 6.14 Mn |
| Sep 30, 2024 | -131,000.00 |
| Sep 30, 2024 | -131,000.00 |
| Mar 31, 2024 | 27,000.00 |
| Mar 31, 2024 | 27,000.00 |
| Dec 31, 2023 | 13,000.00 |
| Dec 31, 2023 | 13,000.00 |
| Sep 30, 2023 | 56,000.00 |
| Sep 30, 2023 | 56,000.00 |